FDA warned Elevated that its website offered compounded semaglutide and tirzepatide with misleading claims they match FDA-approved drugs.
What happened
In August 2025, FDA reviewed website content at https://elevatedhealth.com and observed that the site offered compounded drug products, including semaglutide and tirzepatide. FDA said website claims implied the compounded products were the same as FDA-approved drugs, although compounded drugs are not FDA-approved. The letter cites claims about 'personalized versions' and 'same active ingredient,' including for Semaglutide ODT.
What FDA found
FDA said the website claims for compounded semaglutide and tirzepatide were false or misleading, making the drugs misbranded (mislabeled in a way that violates federal law).
FDCA section 502(a) [21 U.S.C. § 352(a)]FDA said advertising or promotion for the compounded drugs was false or misleading, making the drugs misbranded.
FDCA section 502(bb) [21 U.S.C. § 352(bb)]FDA said the misbranded drugs were introduced or delivered for introduction into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]FDA said receiving, delivering, or offering to deliver misbranded drugs in interstate commerce is also prohibited.
FDCA section 301(c) [21 U.S.C. § 331(c)]
What FDA wants
Within 15 working days of receipt, provide a written response to CDER's Office of Compounding Quality and Compliance describing steps taken to address the violations and prevent recurrence, with related documentation; include reasoning if you believe the products are not in violation.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies and their marketing partners
- brands making comparison claims to FDA-approved drugs
This is a summary. Read the original letter on fda.gov.